Daiichi Sankyo sinks to massive loss on Ranbaxy woes
This article was originally published in Scrip
When it reported its third-quarter results in January, Daiichi Sankyo forecast a group net loss of ¥316.0 billion for the fiscal year, stemming from a massive write-down of goodwill for its acquisition of Ranbaxy.
You may also be interested in...
Asia Deal Watch: RAPT And Hanmi Partner On CCR4 Antagonist Offering Potential In Multiple Cancer Types
RAPT can earn up to $108m in milestones plus sales royalties under the deal. BerGenBio, Piramal partner on developing AML therapy.
Japanese company starts pivotal trial with novel molecule as it looks to build oncology presence.
Gene And Cell Therapies In Asia: Pricing, Manufacturing Stand-Out Issues in Supportive Japan Ecosystem
The Japanese environment for cell and gene therapies and regenerative medicine in general continues to be highly supportive. But will pricing pressures under the NHI scheme move to the fore as more expensive products come to market?